Paper

Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Final analysis of the DAYBREAK open-label extension trial

Multiple Sclerosis Journal · 2025 · Krzysztof W Selmaj, Lawrence Steinman, Giancarlo Comi et al.